Circulating stem cell vary with NYHA stage in heart failure patients

Journal of Cellular and Molecular Medicine

Volumn 15, Issue 8, 2011, Pages 1726-1736

  Fortini, Cinzia ^a   Toffoletto, Barbara ^b   Fucili, Alessandro ^a   Puppato, Elisa ^c   Olivares, Adriana ^a   Beltrami, Antonio Paolo ^c   Fiorelli, Valeria ^a   Bergamin, Natascha ^b   Cesselli, Daniela ^c   Morelli, Cristina ^a   Francolini, Gloria ^a   Ferrari, Roberto ^a   Beltrami, Carlo Alberto ^c  

^a UNIVERSITY OF FERRARA   (Italy)

^b MARIA CECILIA HOSPITAL   (Italy)

^c UNIVERSITY OF UDINE   (Italy)

Author keywords

Cytokines; Endothelial progenitor cells; Haematopoietic stem cells; Heart failure; Mesenchymal stem cells; Myocardial repair

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CXCR4 PROTEIN, HUMAN; CYTOKINE; FIBROBLAST GROWTH FACTOR 2; HGF PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BB; PLATELET-DERIVED GROWTH FACTOR BB; SCATTER FACTOR; STROMAL CELL DERIVED FACTOR 1; THY 1 ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN A;

AGED; ANALYSIS OF VARIANCE; ARTICLE; BLOOD; CLASSIFICATION; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART FAILURE; HEMATOPOIETIC STEM CELL; HOSPITALIZATION; HUMAN; MALE; MESENCHYMAL STEM CELL; METABOLISM; MIDDLE AGED; PATHOLOGY; STEM CELL;

AGED; ANALYSIS OF VARIANCE; ANTIGENS, CD; ANTIGENS, THY-1; CHEMOKINE CXCL12; CYTOKINES; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST GROWTH FACTOR 2; HEART FAILURE; HEMATOPOIETIC STEM CELLS; HEPATOCYTE GROWTH FACTOR; HUMANS; MALE; MESENCHYMAL STEM CELLS; MIDDLE AGED; PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, CXCR4; SEVERITY OF ILLNESS INDEX; STEM CELLS; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79960296244     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2010.01195.x     Document Type: Article

References (34)

1. Orlic D, Kajstura J, Chimenti S, et al. Bone marrow cells regenerate infarcted myocardium. Nature. 2001; 410: 701-5.
2. Li TS, Hayashi M, Ito H, et al. Regeneration of infarcted myocardium by intramyocardial implantation ofex-vivotrasforming growth factor-beta-programmed bone marrow stem cells. Circulation. 2005; 111: 2438-45.
3. Schaefer A, Meyer GP, Fuchs M, et al. Impact of intracoronary bone marrow cell transfer on diastolic function in patients after acute myocardial infarction: results from the BOOST trial. Eur Heart J. 2006; 27: 929-35.
4. Meyer GP, Wollert KC, Lotz J, et al. Intracoronary bone marrow cell transfer after myocardial infarction; eighteen months' follow-up data from the randomized, controlled BOOST (Bone marrow transfer to enhance ST-elevation infarct regeneration) trial. Circulation. 2006; 113: 1287-94.
5. Lunde K, Solheim S, Aakhus R, et al. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med. 2006; 335: 1199-209.
6. Tendera M, Wojakowsky W, Ruzytto W, et al. for the REGENT investigators. Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre myocardial regeneration by Intracoronary infusion of selected population of stem cells in acute myocardial infarction (REGENT) trial. Eur Heart J. 2009; 30: 1313-21.
7. Beitnes JO, Hopp E, Lunde K, et al. Long-term results after intracoronary injection of autologous mononuclear bone marrow cells in acute myocardial infarction: the ASTAMI randomized, controlled study. Heart. 2009; 95: 1983-9.
8. Schächinger V, Assmus B, Erbs S, et al. for the REPAIR-AMI investigators. Intracoronary infusion of bone marrow-derived mononuclear cells abrogates adverse left ventricular remodeling post-acute myocardial infarction: insight from the reinfusion of enriched progenitor cells and infarct remodeling in acute myocardial infarction (REPAIR-AMI) trial. Eur J Heart Fail. 2009; 11: 973-9.
9. Assmus B, Rolf A, Erbs S, et al. for the REPAIR-AMI Investigators. Clinical outcome 2 years after intracoronary administration of bone marrow-derived progenitor cells in acute myocardial infarction. Circ Heart Fail. 2010; 3: 89-96.
10. Valgimigli M, Rigolin GM, Fucili A, et al. CD34+ and endothelial progenitor cells in patients with various degree of congestive heart failure. Circulation. 2004; 110: 1209-12.
11. Task Force for Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of European Society of Cardiology: Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail. 2008; 10: 933-89.
12. He Q, Wan C, Li G. Concise review: multipotent mesenchymal stromal cells in blood. Stem cells. 2007; 25: 69-77.
13. Bryder D, Rossi DJ, Weissman IL. Hematopoietic stem cells: the paradigmatic tissue-specific stem cell. Am J Pathol. 2006; 169: 338-46.
14. Peichev M, Naiyer A, Pereira D, et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood. 2000; 95: 952-8.
15. Handgretinger R, Gordon P, Leimig T, et al. Biology and plasticity of CD133+ hematopoietic stem cells. Ann N Y Acad Sci. 2003; 996: 141-51.
16. Dejana E, Bazzoni G, Lampugnani MG. Vascular endothelial (VE)-cadherin: only an intercellular glue? Exp Cell Res. 1999; 252: 13-9.
17. Kucia M, Dawn B, Hunt G, et al. Cells expressing early cardiac markers reside in the bone marrow and are mobilized into the peripheral blood after myocardial infarction. Circ Res. 2004; 95: 1191-9.
18. Petit I, Jin D, Rafii S. The SDF-1α-CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis. Trends Immunol. 2007; 28: 299-307.
19. Nakamizo A, Marini F, Amano T, et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res. 2005; 65: 3307-18.
20. Ingram DA, Caplice NM, Yoder MC. Unresolved questions, changing definitions and novel paradigms for defining endothelial progenitor cells. Blood. 2005; 106: 1525-31.
21. Pittenger M, Martin B. Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res. 2004; 95: 9-20.
22. Leri A, Kajstura J, Anversa P. Cardiac stem cells and mechanism of myocardial generation. Physiol Rev. 2005; 85: 1373-1416.
23. Pitchford SC, Furze RC, Jones CP, et al. Differential mobilization of subsets of progenitor cells from the bone marrow. Cell Stem Cell. 2009; 4: 62-72.
24. Zhao T, Zhang D, Millard RW, et al. Stem cell homing and angiomyogenesis in transplanted hearts are enhanced by combined intramyocardial SDF-1alpha delivery and endogenous cytokine signaling. Am J Physiol Heart Circ Physiol. 2009; 296: H976-86.
25. Haider H, Jiang S, Idris NM, et al. IGF-1-overexpressing mesenchymal stem cells accelerate bone marrow stem cell mobilizationviaparacrine activation of SDF-1alpha/CXCR4 signaling to promote myocardial repair. Circ Res. 2008; 103: 1300-8.
26. Abbott JD, Huang Y, Liu D, et al. Stromal cell-derived factor-1alpha plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury. Circulation. 2004; 110: 3300-5.
27. Tokunaga A, Oya T, Ishii Y, et al. PDGF receptor beta is a potent regulator of mesenchymal stromal cell function. J Bone Miner Res. 2008; 23: 1519-28.
28. Das H, George JC, Joseph M, et al. Stem cell therapy with overexpressed VEGF and PDGF genes improves cardiac function in a rat infarct model. PLoS One. 2009; 4: e7325.
29. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999; 284: 143-7.
30. Vulliet PR, Greeley M, Halloran SM, et al. Intra-coronary arterial injection of the mesenchymal stromal cells and microinfarction in dogs. Lancet. 2004; 363: 783-4.
31. Rafii S, Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med. 2003; 9: 702-12.
32. Dufour C, Corcione A, Svahn J, et al. TNF-alpha and IFN-gamma are overexpressed in the bone marrow of Fanconi anemia patients and TNF-alpha suppresses erytropoiesisin vitro. Blood. 2003; 102: 2053-9.
33. Grisar J, Aletaha D, Steiner CW, et al. Endothelial progenitor cells in active rheumatoid arthritis: effects of tumour necrosis factor and glucocorticoid therapy. Ann Rheum Dis. 2007; 66: 1284-8.
34. Crisostomo PR, Wang Y, Markel TA, et al. Human mesenchymal stem cells stimulated by TNF-alpha, LPS, or hypoxia produce growth factors by an NF kappa B- but not JNK-dependent mechanism. Am J Physiol Cell Physiol. 2008; 294: C675-82.